KR20250034041A - 혈중 ldl 콜레스테롤 저하제 - Google Patents

혈중 ldl 콜레스테롤 저하제 Download PDF

Info

Publication number
KR20250034041A
KR20250034041A KR1020247043248A KR20247043248A KR20250034041A KR 20250034041 A KR20250034041 A KR 20250034041A KR 1020247043248 A KR1020247043248 A KR 1020247043248A KR 20247043248 A KR20247043248 A KR 20247043248A KR 20250034041 A KR20250034041 A KR 20250034041A
Authority
KR
South Korea
Prior art keywords
solvate
salt
blood ldl
benzoxazol
methoxyphenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247043248A
Other languages
English (en)
Korean (ko)
Inventor
료헤이 타니가와
Original Assignee
교와 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 교와 가부시키가이샤 filed Critical 교와 가부시키가이샤
Publication of KR20250034041A publication Critical patent/KR20250034041A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247043248A 2022-07-15 2023-07-14 혈중 ldl 콜레스테롤 저하제 Pending KR20250034041A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2022-113930 2022-07-15
JP2022113930 2022-07-15
PCT/JP2023/025980 WO2024014524A1 (ja) 2022-07-15 2023-07-14 血中ｌｄｌコレステロール低下剤

Publications (1)

Publication Number Publication Date
KR20250034041A true KR20250034041A (ko) 2025-03-10

Family

ID=89536850

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247043248A Pending KR20250034041A (ko) 2022-07-15 2023-07-14 혈중 ldl 콜레스테롤 저하제

Country Status (8)

Country Link
US (1) US20260014122A1 (https=)
EP (1) EP4556006A4 (https=)
JP (1) JPWO2024014524A1 (https=)
KR (1) KR20250034041A (https=)
CN (1) CN119546300A (https=)
JO (1) JOP20250007A1 (https=)
TW (1) TW202408500A (https=)
WO (1) WO2024014524A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023777A1 (ja) 2003-09-03 2005-03-17 Kowa Co., Ltd. Ppar活性化化合物及びこれを含有する医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI696462B (zh) * 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
DK3275438T3 (da) * 2016-07-29 2021-01-18 Kowa Co Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko
JP2021506907A (ja) * 2017-12-21 2021-02-22 興和株式会社 高トリグリセライド血症の治療方法
US11446282B2 (en) * 2017-12-21 2022-09-20 Kowa Company, Ltd. Methods of treating mixed dyslipidemia and hypertriglycertdemia
US20240277745A1 (en) * 2021-05-27 2024-08-22 Kowa Company, Ltd Pemafibrate and/or tofogliflozin for use in treating liver disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023777A1 (ja) 2003-09-03 2005-03-17 Kowa Co., Ltd. Ppar活性化化合物及びこれを含有する医薬組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Authors/Task Force Members 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019 Nov; 290: 140-205
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18; 139(25): e1082-e1143
Rodrigo Alonso1, Ada Cuevas1, Alberto Cafferata. Diagnosis and Management of Statin Intolerance. J Atheroscler Thromb, 2019; 26: 207-215
스타틴 불내 진료 지침 작성 워킹 그룹: 가지나미 고지, 츠카모토 가즈히사, 고바 신지 et al. 스타틴 불내에 관한 진료 지침 2018
일본 동맥 경화 학회(편): 동맥 경화성 질환 예방 가이드 라인 2017년판. 일본 동맥 경화 학회, 2017

Also Published As

Publication number Publication date
WO2024014524A1 (ja) 2024-01-18
JOP20250007A1 (ar) 2025-01-13
EP4556006A4 (en) 2026-01-07
CN119546300A (zh) 2025-02-28
TW202408500A (zh) 2024-03-01
EP4556006A1 (en) 2025-05-21
US20260014122A1 (en) 2026-01-15
JPWO2024014524A1 (https=) 2024-01-18

Similar Documents

Publication Publication Date Title
US10632112B2 (en) Combination therapy for treatment of HBV infections
US20240398746A1 (en) Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
AU2016233257A1 (en) Fixed dose combinations comprising ETC1002 and one or more statins for treating or reducing cardiovascular risk
WO2011032175A1 (en) Combination formulations of tranilast and allopurinol and methods related thereto
TW201817425A (zh) 用於治療非酒精性脂肪肝疾病之醫藥組成物及方法
JP2024081650A (ja) 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法
KR20250034041A (ko) 혈중 ldl 콜레스테롤 저하제
JP6454436B1 (ja) ペマフィブラートを含有する医薬
US20210322375A1 (en) Combination drug formulations for treating patients with cardiovascular disease and associated conditions
US20240293369A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
US20100305074A1 (en) Niacin-based pharmaceutical compositions
WO2022224962A1 (ja) 脂質異常症又は心臓血管病の予防・治療のための組合せ医薬
TW202408499A (zh) 降低血中肌肉生長抑制素之藥劑
WO2025168652A1 (en) Azd-0780 in combination with a statin for use in lowering ldl-c levels and treating cardiovacular diseases
JP2005533851A (ja) 高コレステロール血症処置用物質および方法
CN101534825A (zh) 含有贝特类药物的制剂及其制备方法
JP2007308484A (ja) 高脂血症の予防及び／又は治療のための医薬
WO2000028984A1 (fr) Remedes agissant contre un trouble fonctionnel du tractus digestif

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20241227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application